GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
Portfolio Pulse from Vandana Singh
GSK's phase 3 trial shows that co-administering its RSV vaccine, Arexvy, with its shingles vaccine, Shingrix, in older adults results in a non-inferior immune response compared to separate administration. The trial data will support regulatory submissions.
September 18, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK's use of the QS-21 STIMULON adjuvant, licensed from Agenus Inc's subsidiary, in its vaccines highlights the importance of Agenus's adjuvant technology in successful vaccine development.
The use of Agenus's adjuvant in GSK's successful vaccine trials underscores the value of Agenus's technology, potentially leading to increased interest and partnerships, positively impacting its stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
GSK's phase 3 trial indicates that co-administering Arexvy with Shingrix in older adults is effective and safe, showing a non-inferior immune response. This supports future regulatory submissions, potentially boosting GSK's vaccine portfolio.
The successful trial results for co-administering Arexvy and Shingrix could enhance GSK's vaccine offerings, leading to potential regulatory approvals and increased market share. This is likely to positively impact GSK's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100